eFFECTOR Therapeutics Inc (EFTR)
followers
·
Follow
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
CEO:
Stephen T. Worland
Employees:
10
142 NORTH CEDROS AVENUE, SUITE B, SOLANA BEACH, CA, 92075
(858) 925-8215
Date | Ratio |
---|---|
2024-01-12 | 1:25 |
eFFECTOR Therapeutics, Inc. engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E)
All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|